Poster
PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy
Author
Cem Akin
Condition
Systemic Mastocytosis
Drug target
KIT D816V
Drug moa
KIT D816V inhibitor
Source url
s3://convoke-optic-posters/2024-05-10/Blueprint-Medicines-ASH-2019-Avapritinib-SM-Poster.pdf
24 organizations
1 product
Product
AvapritinibOrganization
University of MichiganOrganization
Brigham and Women’s HospitalOrganization
University Medical Center GroningenOrganization
Erasmus Medical CenterOrganization
University of SalernoOrganization
ARUP LaboratoriesOrganization
Charité-Universitätsmedizin BerlinOrganization
St. Michael’s HospitalOrganization
University Hospital RWTH AachenOrganization
Technical University MunichOrganization
Ashfield HealthcareOrganization
Blueprint MedicinesOrganization
Huntsman Cancer InstituteOrganization
Columbia University Medical CenterOrganization
Guy’s and St Thomas NHS Foundation TrustOrganization
Dana Farber Cancer Institute, Boston, MAOrganization
Odense University HospitalOrganization
University of BaselOrganization
University Medical Centre MannheimOrganization
Verona University HospitalOrganization
Universitätsklinikum Schleswig-Holstein